- Home
- Middle East And Africa Psychedelic Drugs Market

Middle East and Africa Psychedelic Drugs Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-273 | No of pages: 110 | Format:
Middle East and Africa psychedelic drugs market is projected to register a CAGR of 15.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
Middle East and Africa Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Country (Saudi Arabia, UAE, Israel and Egypt) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Middle East and Africa psychedelic drugs market are:
Rise in product approvals
Ongoing clinical trials
Market Players:
The key market players for Middle East and Africa psychedelic drugs market are listed below:
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
Hikma Pharmaceuticals PLC
Pfizer Inc.
F. Hoffmann-La Roche Ltd
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET 1.4 LIMITATIONS 1.5 MARKETS COVERED 2 MARKET SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 MULTIVARIATE MODELLING 2.7 TYPE OF PSYCHEDELIC DRUGS LIFELINE CURVE 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.9 DBMR MARKET POSITION GRID 2.10 MARKET APPLICATION COVERAGE GRID 2.11 VENDOR SHARE ANALYSIS 2.12 SECONDARY SOURCES 2.13 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHT 5 EPIDEMIOLOGY 6 REGULATORY FRAMEWORK: MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET 6.1 REGULATORY SCENARIO IN INDIA 6.2 REGULATORY SCENARIO IN UAE 6.3 REGULATORY SCENARIO IN AFRICA 6.4 REGULATORY SCENARIO IN THE U.S. 6.5 REGULATORY SCENARIO IN BRAZIL 6.6 REGULATORY SCENARIO IN THE U.K. 7 PIPELINE ANALYSIS 8 MARKET OVERVIEW 8.1 DRIVERS 8.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 8.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 8.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 8.1.4 ONGOING CLINICAL TRIALS 8.1.5 RISE IN PRODUCT APPROVALS 8.2 RESTRAINTS 8.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 8.2.2 HIGH COST OF PSYCHEDELIC DRUGS 8.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 8.3 OPPORTUNITIES 8.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 8.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 8.3.3 UPCOMING REHABILITATION CENTERS 8.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 8.4 CHALLENGES 8.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 8.4.2 RISE IN ALTERNATIVES 8.4.3 OTHER TREATMENT OPTIONS 9 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET 9.1 IMPACT ON PRICE 9.2 IMPACT ON DEMAND 9.3 IMPACT ON SUPPLY CHAIN 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 9.5 CONCLUSION 10 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUG MARKET, BY SOURCE 10.1 OVERVIEW 10.2 SYNTHETIC 10.3 NATURAL 11 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY TYPE 11.1 OVERVIEW 11.2 EMPATHOGENS 11.3 DISSOCIATIVES 11.4 OTHERS 12 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY DRUGS 12.1 OVERVIEW 12.2 GAMMA-HYDROXYBUTYRIC ACID 12.3 KETAMINE 12.4 PSILOCYBIN 12.5 OTHERS 13 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY APPPLICATION 13.1 OVERVIEW 13.2 NARCOLEPSY 13.3 TREATMENT RESISTANT DEPRESSION 13.4 MAJOR DEPRESSIVE DISORDER 13.5 OPIATE ADDICTION 13.6 POST-TRAUMATIC STRESS DISORDER 13.7 OTHERS 14 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUG MARKET, BY ROUTE OF ADMINISTRATION 14.1 OVERVIEW 14.2 ORAL 14.3 INHALATION 14.4 INJECTABLE 15 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY END USER 15.1 OVERVIEW 15.2 HOSPITALS 15.3 SPECIALTY CLINICS 15.4 HOMECARE 15.5 OTHERS 16 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 16.1 OVERVIEW 16.2 HOSPITAL PHARMACY 16.3 RETAIL PHARMACY 16.4 ONLINE PHARMACY 17 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET, BY REGION 17.1 MIDDLE EAST & AFRICA 17.1.1 SAUDI ARABIA 17.1.2 ISRAEL 17.1.3 EGYPT 17.1.4 UAE 18 MIDDLE EAST AND AFRICA PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 19 SWOT 20 COMPANY PROFILE 20.1 JAZZ PHARMACEUTICALS, INC. 20.1.1 COMPANY SNAPSHOT 20.1.2 REVENUE ANALYSIS 20.1.3 COMPANY SHARE ANALYSIS 20.1.4 PRODUCT PORTFOLIO 20.1.5 RECENT DEVELOPMENTS 20.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 20.2.1 COMPANY SNAPSHOT 20.2.2 REVENUE ANALYSIS 20.2.3 COMPANY SHARE ANALYSIS 20.2.4 PRODUCT PORTFOLIO 20.2.5 RECENT DEVELOPMENTS 20.3 PFIZER INC. 20.3.1 REVENUE ANALYSIS 20.3.2 COMPANY SHARE ANALYSIS 20.3.3 PRODUCT PORTFOLIO 20.3.4 RECENT DEVELOPMENTS 20.4 VERRIAN 20.4.1 COMPANY SNAPSHOT 20.4.2 COMPANY SHARE ANALYSIS 20.4.3 PRODUCT PORTFOLIO 20.4.4 RECENT DEVELOPMENT 20.5 AVADEL 20.5.1 COMPANY SNAPSHOT 20.5.2 REVENUE ANALYSIS 20.5.3 COMPANY SHARE ANALYSIS 20.5.4 RECENT DEVELOPMENTS 20.6 CELON PHARMA S.A. 20.6.1 COMPANY SNAPSHOT 20.6.2 PIPELINE PORTFOLIO 20.6.3 RECENT DEVELOPMENTS 20.7 COMPASS 20.7.1 COMPANY SNAPSHOT 20.7.2 PRODUCT PORTFOLIO 20.7.3 RECENT DEVELOPMENTS 20.8 F. HOFFMANN-LA ROCHE LTD 20.8.1 COMPANY SNAPSHOT 20.8.2 REVENUE ANALYSIS 20.8.3 PRODUCT PORTFOLIO 20.8.4 RECENT DEVELOPMENT 20.9 HIKMA PHARMACEUTICALS PLC 20.9.1 COMPANY SNAPSHOT 20.9.2 REVENUE ANALYSIS 20.9.3 PRODUCT PORTFOLIO 20.9.4 RECENT DEVELOPMENTS 20.10 NEURORX, INC. 20.10.1 COMPANY SNAPSHOT 20.10.2 PRODUCT PORTFOLIO 20.10.3 RECENT DEVELOPMENTS 20.11 PHARMATHER INC. 20.11.1 COMPANY SNAPSHOT 20.11.2 PRODUCT PORTFOLIO 20.11.3 RECENT DEVELOPMENTS 20.12 USONAINSTITUTE.ORG 20.12.1 INSTITUTE SNAPSHOT 20.12.2 PIPELINE PORTFOLIO 20.12.3 RECENT DEVELOPMENTS 21 QUESTIONNAIRE 22 RELATED REPORTSSegmentation
Short Description Middle East and Africa Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Country (Saudi Arabia, UAE, Israel and Egypt) Industry Trends and Forecast to 2028 Market Definition Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychedelic drugs have the ability to change or enhance the senosory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences. Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD. Market Segmentation The psychedelic drugs market is segmented into seven notable segments which are based on the source, type, drugs, application, route of administration, end user and distribution channel. On the basis of source, the psychedelic drugs market is segmented into synthetic and natural On the basis of type, the psychedelic drugs market is segmented into dissociatives, empathogens and others On the basis of drugs, the psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others On the basis of application, the psychedelic drugs market is segmented into narcolepsy, treatment resistant depression, post-traumatic stress disorder, major depressive disorder, opiate addiction and others On the basis of route of administration, the psychedelic drugs market is segmented into oral, inhalation and injectable On the basis of end user, the psychedelic drugs market is segmented into hospitals, specialty clinics, homecare and others On the basis of distribution channel, the psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy Market Players The key market players for Middle East and Africa psychedelic drugs market are listed below: Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) Hikma Pharmaceuticals PLC Pfizer Inc. F. Hoffmann-La Roche LtdMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.